Lymphatic Filariasis Clinical Trial
Official title:
Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis
Verified date | July 2020 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
This prospective study will enroll and follow 60 loiasis patients with high worm burden to monitor the spontaneous release of filarial antigen in peripheral blood. This study will define the cross-reactive antigen profile of persons with spontaneous loiasis antigenemia, and determine whether it varies with time.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | December 31, 2021 |
Est. primary completion date | May 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Ability to give informed consent - Loiasis Mf count > 20,000 Mf/mL - Resident of study area - No evidence of severe or systemic comorbidities - Consent to storage of blood samples for future study Exclusion Criteria: - Subject plans to move from the study area during subsequent 12 months |
Country | Name | City | State |
---|---|---|---|
Cameroon | Centre for Research on Filariasis and other Tropical Diseases (CRFilMT) | Yaoundé |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | Centre for Research on Filariasis and other Tropical Diseases, Doris Duke Charitable Foundation |
Cameroon,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | prevalence of specific cross-reactive L. loa antigens at baseline | Prevalence of filariasis test strip (FTS) positive individuals at screening. Cross-reactive proteins in plasma will be identified by mass-spectrometry to identify a cross-reactive biomarker | 1 day | |
Secondary | Recurrence of cross-reactive antigenemia | To determine if the same antigens are present at each follow up | quarterly for 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00375583 -
Effect of Albendazole Dose on Clearance of Filarial Worms
|
Phase 2 | |
Completed |
NCT03664063 -
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 2 | |
Recruiting |
NCT04844905 -
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
|
Phase 3 | |
Completed |
NCT01975441 -
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
|
Phase 2 | |
Completed |
NCT01629771 -
Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
|
N/A | |
Completed |
NCT01905423 -
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
|
||
Completed |
NCT02784743 -
Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali
|
Phase 4 | |
Completed |
NCT03036059 -
Twice Yearly Treatment for the Control of LF
|
Phase 4 | |
Completed |
NCT01905436 -
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
|
||
Completed |
NCT02509481 -
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
|
Phase 2/Phase 3 | |
Completed |
NCT03268252 -
Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
|
||
Completed |
NCT02927496 -
A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
|
Phase 3 | |
Completed |
NCT02899936 -
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
|
N/A | |
Completed |
NCT00511004 -
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
|
Phase 2 | |
Completed |
NCT02974049 -
Lymphatic Filariasis (LF) in Ivory Coast
|
N/A | |
Terminated |
NCT01213576 -
Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi
|
N/A | |
Completed |
NCT02929121 -
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
|
Phase 3 | |
Completed |
NCT00339417 -
Effect of Albendazole Dose on Clearance of Filarial Worms
|
Phase 2 | |
Completed |
NCT02032043 -
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
|
||
Withdrawn |
NCT01903057 -
Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
|
Phase 4 |